SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of
March 2007
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Research Collaborators Present
Combination Reovirus and Cyclophosphamide Treatment Results at
International Oncolytic Virus Conference
CALGARY, AB, March 19, 2007 Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY)
announced today that Dr. Richard Vile of the Mayo College of Medicine, Rochester, Minnesota
delivered an oral presentation at the 4th International Conference on Oncolytic Viruses
as Cancer Therapeutics in Carefree, Arizona on Saturday, March 17 covering a study of systemic
administration of reovirus in combination with cyclophosphamide, an immune modulator. The
conference was held from March 14 through 17, 2007.
The work demonstrated that systemic administration of reovirus in combination with cyclophosphamide
enhanced tumour regression in a melanoma animal model without increasing toxicity. In addition, the
investigators were able to demonstrate that the addition of cyclophosphamide significantly
increased the amount of reovirus replicating within the tumour.
The investigators concluded that the addition of cyclophosphamide may lead to improved efficacy of
REOLYSIN® treatment.
Our ongoing clinical trials are examining REOLYSIN® in combination with
gemcitabine, paclitaxel/carboplatin and docetaxel, said Dr. Matt Coffey, Chief Scientific Officer
of Oncolytics. These new results are remarkable. This promising preclinical work confirms
Oncolytics commitment to continuing to investigate moving REOLYSIN® and other existing
chemotherapies into human clinical trials.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I and
Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials presented at this conference with respect to REOLYSIN®, the
Companys expectations related to the results of trials investigating delivery of
REOLYSIN®, and the Companys belief as to the potential of REOLYSIN® as a
cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Companys actual results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the
success and timely completion of clinical studies and trials, the Companys ability to successfully
commercialize REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the
Companys quarterly and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group
|
|
The Investor Relations Group |
Cathy Ward
|
|
Nick Hurst
|
|
Erika Moran |
210, 1167 Kensington Cr NW
|
|
600, 205 5th Ave. SW
|
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7
|
|
Calgary, Alberta T2P 2V7
|
|
New York, NY 10004 |
Tel: 403.670.7377
|
|
Tel: 403.538.4845
|
|
Tel: 212.825.3210 |
Fax: 403.283.0858
|
|
Fax: 403.266.2453
|
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca |
|
nhurst@equicomgroup.com |
|
emoran@investorrelationsgroup.com |
-30-